62 results
8-K
EX-4.1
GLUE
Monte Rosa Therapeutics Inc
16 May 24
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
4:06pm
. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares
8-K
EX-1.1
GLUE
Monte Rosa Therapeutics Inc
16 May 24
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
4:06pm
be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither the Representative nor … . The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares
424B5
GLUE
Monte Rosa Therapeutics Inc
16 May 24
Prospectus supplement for primary offering
4:04pm
on or about May 20, 2024.
Joint Book-Running Managers
TD Cowen
Wedbush PacGrow
Prospectus supplement dated May 15, 2024
We are responsible
424B5
GLUE
Monte Rosa Therapeutics Inc
15 May 24
Prospectus supplement for primary offering
4:04pm
Wedbush PacGrow
Prospectus supplement dated , 2024
We are responsible for the information contained and incorporated by reference in this prospectus
8-K
EX-10.1
oek27 tmagliid74j86
26 Oct 23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
5:01pm
8-K
EX-4.1
fb66b4yiz19askuutoez
26 Oct 23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
5:01pm
PRE 14A
v1j8r9wia4 bo
12 Apr 23
Preliminary proxy
4:07pm